Trade Gyre Therapeutics Inc - GYRE CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.1516 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 0.01 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Gyre Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 23.3492 |
Open* | 24.5992 |
1-Year Change* | 4388.09% |
Day's Range* | 16.0992 - 24.5992 |
52 wk Range | 2.83-17.41 |
Average Volume (10 days) | 90.13K |
Average Volume (3 months) | 769.23K |
Market Cap | 32.23M |
P/E Ratio | -100.00K |
Shares Outstanding | 2.53M |
Revenue | N/A |
EPS | -20.60 |
Dividend (Yield %) | N/A |
Beta | 1.29 |
Next Earnings Date | Mar 28, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 1, 2023 | 23.3492 | 1.1300 | 5.09% | 22.2192 | 25.0292 | 21.6992 |
Nov 30, 2023 | 23.3092 | -2.5900 | -10.00% | 25.8992 | 25.8992 | 21.3292 |
Nov 29, 2023 | 26.0892 | 0.3400 | 1.32% | 25.7492 | 26.8992 | 24.0092 |
Nov 28, 2023 | 24.0092 | 3.0000 | 14.28% | 21.0092 | 26.2992 | 21.0092 |
Nov 27, 2023 | 20.8192 | 1.3200 | 6.77% | 19.4992 | 20.8992 | 17.5292 |
Nov 24, 2023 | 19.0392 | 1.8300 | 10.63% | 17.2092 | 19.8992 | 17.2092 |
Nov 22, 2023 | 16.0992 | 2.8600 | 21.60% | 13.2392 | 16.4092 | 13.2392 |
Nov 21, 2023 | 12.4792 | -1.7200 | -12.11% | 14.1992 | 14.1992 | 11.7992 |
Nov 20, 2023 | 14.4992 | -1.1000 | -7.05% | 15.5992 | 17.2992 | 14.2692 |
Nov 17, 2023 | 14.4092 | 1.4100 | 10.85% | 12.9992 | 14.4992 | 12.9992 |
Nov 16, 2023 | 12.8192 | 0.2200 | 1.75% | 12.5992 | 13.7192 | 12.5992 |
Nov 15, 2023 | 12.1492 | 2.6500 | 27.90% | 9.4992 | 12.6592 | 9.4992 |
Nov 14, 2023 | 9.2892 | 0.2000 | 2.20% | 9.0892 | 9.4792 | 8.9592 |
Nov 13, 2023 | 8.8592 | 0.0500 | 0.57% | 8.8092 | 9.0992 | 8.6992 |
Nov 10, 2023 | 8.6992 | -0.4200 | -4.61% | 9.1192 | 9.1992 | 8.2992 |
Nov 9, 2023 | 8.6692 | -0.8400 | -8.83% | 9.5092 | 10.2492 | 8.4992 |
Nov 8, 2023 | 9.1992 | 1.0100 | 12.33% | 8.1892 | 9.2492 | 8.0992 |
Nov 7, 2023 | 8.0492 | 0.6900 | 9.38% | 7.3592 | 8.0992 | 7.3592 |
Nov 6, 2023 | 7.1592 | 0.4100 | 6.07% | 6.7492 | 7.3292 | 6.7492 |
Nov 3, 2023 | 6.4392 | 0.0700 | 1.10% | 6.3692 | 6.5192 | 6.3192 |
Gyre Therapeutics Inc Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 28, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q4 2023 Catalyst Biosciences Inc Earnings Release Q4 2023 Catalyst Biosciences Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0.794 | 7.338 | 20.948 | 0 | 0.006 |
Revenue | 0.794 | 7.338 | 20.948 | 0 | 0.006 |
Total Operating Expense | 9.225 | 95.232 | 78.318 | 57.277 | 33.828 |
Selling/General/Admin. Expenses, Total | 16.966 | 18.963 | 16.18 | 13.418 | 12.354 |
Research & Development | 12.437 | 68.889 | 52.175 | 43.859 | 21.474 |
Operating Income | -8.431 | -87.894 | -57.37 | -57.277 | -33.822 |
Interest Income (Expense), Net Non-Operating | 0.537 | 0.039 | 0.561 | 2.145 | 2.233 |
Gain (Loss) on Sale of Assets | 0 | -0.116 | |||
Net Income Before Taxes | -7.894 | -87.933 | -56.241 | -55.178 | -30.055 |
Net Income After Taxes | -8.242 | -87.933 | -56.241 | -55.178 | -30.055 |
Net Income Before Extra. Items | -8.242 | -87.933 | -56.241 | -55.178 | -30.055 |
Net Income | -8.242 | -87.933 | -56.241 | -55.178 | -30.055 |
Income Available to Common Excl. Extra. Items | -8.242 | -87.933 | -56.241 | -55.178 | -30.055 |
Income Available to Common Incl. Extra. Items | -8.242 | -87.933 | -56.241 | -55.178 | -30.055 |
Diluted Net Income | -8.242 | -87.933 | -56.241 | -55.178 | -30.055 |
Diluted Weighted Average Shares | 31.5457 | 30.641 | 19.1793 | 12.0045 | 11.2139 |
Diluted EPS Excluding Extraordinary Items | -0.26127 | -2.86978 | -2.93238 | -4.59645 | -2.68016 |
Diluted Normalized EPS | -0.30083 | -2.86978 | -2.89067 | -4.59645 | -2.66982 |
Total Extraordinary Items | |||||
Total Adjustments to Net Income | 0 | ||||
Other, Net | 0 | -0.078 | 0.568 | -0.046 | 1.65 |
Cost of Revenue, Total | 0.798 | 7.38 | 9.163 | ||
Gross Profit | -0.004 | -0.042 | 11.785 | ||
Unusual Expense (Income) | -20.976 | 0.8 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue, Total | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 1.623 | 2.543 | -0.178 | 40.274 | 5.166 |
Selling/General/Admin. Expenses, Total | 2.408 | 2.225 | 3.97 | 4.165 | 4.363 |
Research & Development | 0.415 | 0.318 | 0.588 | 0.66 | 0.803 |
Operating Income | -1.623 | -2.543 | 0.178 | -40.274 | -5.166 |
Interest Income (Expense), Net Non-Operating | 0.047 | 0.073 | 0.096 | 0.167 | 0.283 |
Other, Net | 0.001 | -0.001 | |||
Net Income Before Taxes | -1.576 | -2.47 | 0.274 | -40.106 | -4.884 |
Net Income After Taxes | -1.576 | -2.472 | 0.26 | -40.454 | -4.884 |
Net Income Before Extra. Items | -1.576 | -2.472 | 0.26 | -40.454 | -4.884 |
Net Income | -1.576 | -2.472 | 0.26 | -40.454 | -4.884 |
Income Available to Common Excl. Extra. Items | -1.576 | -2.472 | 0.26 | -40.454 | -4.884 |
Income Available to Common Incl. Extra. Items | -1.576 | -2.472 | 0.26 | -40.454 | -4.884 |
Diluted Net Income | -1.576 | -2.472 | 0.26 | -40.454 | -4.884 |
Diluted Weighted Average Shares | 37.9768 | 37.8001 | 37.9843 | 31.7649 | 31.4845 |
Diluted EPS Excluding Extraordinary Items | -0.0415 | -0.0654 | 0.00684 | -1.27354 | -0.15512 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.0415 | -0.0654 | -0.0742 | -0.15821 | -0.15512 |
Unusual Expense (Income) | 0 | 0 | -4.736 | 35.449 | 0 |
Other Operating Expenses, Total | -1.2 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 28.206 | 51.476 | 89.51 | 96.066 | 123.991 |
Cash and Short Term Investments | 21.666 | 46.851 | 79.354 | 76.865 | 120.127 |
Cash & Equivalents | 21.666 | 44.347 | 30.36 | 15.369 | 31.213 |
Short Term Investments | 0 | 2.504 | 48.994 | 61.496 | 88.914 |
Total Receivables, Net | 5 | 1.818 | 3.313 | 15 | |
Accounts Receivable - Trade, Net | 5 | 1.818 | 3.313 | 15 | |
Prepaid Expenses | 1.54 | 2.807 | 6.843 | 4.201 | 3.814 |
Other Current Assets, Total | 0 | 0.05 | |||
Total Assets | 28.444 | 55.662 | 94.846 | 98.554 | 124.92 |
Property/Plant/Equipment, Total - Net | 0.07 | 3.714 | 2.265 | 2.231 | 0.386 |
Property/Plant/Equipment, Total - Gross | 0.671 | ||||
Accumulated Depreciation, Total | -0.285 | ||||
Other Long Term Assets, Total | 0.168 | 0.472 | 0.528 | 0.257 | 0.543 |
Total Current Liabilities | 16.824 | 14.165 | 17.796 | 28.899 | 4.801 |
Accounts Payable | 0.194 | 6.419 | 5.931 | 4.279 | 1.248 |
Accrued Expenses | 4.072 | 7.516 | 9.882 | 9.62 | 3.538 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 12.558 | 0.23 | 1.983 | 15 | 0.015 |
Total Liabilities | 16.824 | 14.573 | 18.777 | 30.218 | 4.975 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0 | 0.408 | 0.981 | 1.319 | 0.174 |
Total Equity | 11.62 | 41.089 | 76.069 | 68.336 | 119.945 |
Common Stock | 0.037 | 0.031 | 0.022 | 0.012 | 0.012 |
Additional Paid-In Capital | 389.21 | 443.752 | 390.803 | 326.81 | 323.279 |
Retained Earnings (Accumulated Deficit) | -410.936 | -402.694 | -314.761 | -258.52 | -203.342 |
Other Equity, Total | 0 | 0.005 | 0.034 | -0.004 | |
Total Liabilities & Shareholders’ Equity | 28.444 | 55.662 | 94.846 | 98.554 | 124.92 |
Total Common Shares Outstanding | 2.51723 | 2.09409 | 1.47326 | 0.80276 | 0.79701 |
Redeemable Preferred Stock | 33.309 | 0 | |||
Total Preferred Shares Outstanding | 0 | 0 | |||
Long Term Investments | 0 | 2.543 | |||
Preferred Stock - Non Redeemable, Net | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 5.132 | 7.62 | 14.014 | 28.206 | 30.246 |
Cash and Short Term Investments | 2.228 | 6.923 | 8.099 | 21.666 | 23.09 |
Cash & Equivalents | 2.228 | 6.923 | 8.099 | 21.666 | 23.09 |
Short Term Investments | 0 | 0 | |||
Total Receivables, Net | 1.2 | 0 | 5 | 5 | 5 |
Accounts Receivable - Trade, Net | 0 | 0 | 5 | 5 | 5 |
Prepaid Expenses | 1.704 | 0.697 | 0.915 | 1.54 | 2.156 |
Total Assets | 9.964 | 12.394 | 18.75 | 28.444 | 31.019 |
Property/Plant/Equipment, Total - Net | 0 | 0 | 0.018 | 0.07 | 0.605 |
Other Long Term Assets, Total | 0.168 | 0.168 | 0.168 | 0.168 | 0.168 |
Total Current Liabilities | 1.783 | 2.793 | 6.844 | 16.824 | 1.644 |
Accounts Payable | 0.158 | 0.005 | 0.016 | 0.194 | 0.041 |
Accrued Expenses | 1.625 | 2.788 | 1.828 | 4.072 | 1.603 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0 | 5 | 12.558 | 0 |
Total Liabilities | 6.447 | 7.399 | 11.394 | 16.824 | 1.644 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 4.664 | 4.606 | 4.55 | 0 | 0 |
Total Equity | 3.517 | 4.995 | 7.356 | 11.62 | 29.375 |
Common Stock | 0.037 | 0.037 | 0.037 | 0.037 | 0.031 |
Additional Paid-In Capital | 384.895 | 384.797 | 384.686 | 389.21 | 399.826 |
Retained Earnings (Accumulated Deficit) | -414.724 | -413.148 | -410.676 | -410.936 | -370.482 |
Other Equity, Total | |||||
Total Liabilities & Shareholders’ Equity | 9.964 | 12.394 | 18.75 | 28.444 | 31.019 |
Total Common Shares Outstanding | 2.532 | 2.53179 | 2.51745 | 2.51723 | 2.09944 |
Long Term Investments | |||||
Preferred Stock - Non Redeemable, Net | 0 | ||||
Redeemable Preferred Stock | 33.309 | 33.309 | 33.309 | 33.309 | |
Note Receivable - Long Term | 4.664 | 4.606 | 4.55 | ||
Total Preferred Shares Outstanding | 0.01234 | 0.01234 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -8.242 | -87.933 | -56.241 | -55.178 | -30.055 |
Cash From Operating Activities | -33.096 | -83.755 | -55.048 | -43.613 | -28.553 |
Cash From Operating Activities | 0.23 | 0.29 | 0.138 | 0.146 | 0.149 |
Non-Cash Items | -20.139 | 3.405 | 3.627 | 3.204 | 2.722 |
Changes in Working Capital | -4.945 | 0.483 | -2.572 | 8.215 | -1.369 |
Cash From Investing Activities | 55.426 | 48.189 | 9.663 | 27.392 | -71.321 |
Capital Expenditures | 0 | -0.839 | -0.267 | -0.064 | -0.376 |
Other Investing Cash Flow Items, Total | 55.426 | 49.028 | 9.93 | 27.456 | -70.945 |
Cash From Financing Activities | -45.011 | 49.553 | 60.376 | 0.327 | 111.332 |
Issuance (Retirement) of Stock, Net | 0.02 | 49.553 | 60.376 | 0.327 | 116.414 |
Issuance (Retirement) of Debt, Net | 0 | -5.082 | |||
Net Change in Cash | -22.681 | 13.987 | 14.991 | -15.894 | 11.458 |
Total Cash Dividends Paid | -45.031 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 0.26 | -8.242 | 32.212 | 37.096 | -14.536 |
Cash From Operating Activities | -6.216 | -33.096 | -31.621 | -24.344 | -12.05 |
Cash From Operating Activities | 0.003 | 0.23 | 0.22 | 0.18 | 0.113 |
Non-Cash Items | -4.526 | -20.139 | -55.85 | -56.184 | 0.715 |
Changes in Working Capital | -1.953 | -4.945 | -8.203 | -5.436 | 1.658 |
Cash From Investing Activities | 0.411 | 55.426 | 55.375 | 55.375 | 2.504 |
Other Investing Cash Flow Items, Total | 0.411 | 55.426 | 55.375 | 55.375 | 2.504 |
Cash From Financing Activities | -7.762 | -45.011 | -45.011 | 0.016 | 0.016 |
Issuance (Retirement) of Stock, Net | 0.002 | 0.02 | 0.02 | 0.016 | 0.016 |
Net Change in Cash | -13.567 | -22.681 | -21.257 | 31.047 | -9.53 |
Capital Expenditures | 0 | 0 | 0 | ||
Total Cash Dividends Paid | -7.764 | -45.031 | -45.031 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Catalyst Biosciences, Inc. Company profile
About Catalyst Biosciences Inc
Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Catalyst Biosciences Inc revenues decreased 74% to $4.9M. Net loss increased 81% to $67.6M. Revenues reflect License decrease from $15.1M to $0K. Higher net loss reflects Research and development increase of 3% to $38.3M (expense), General and administrative - Balancing v increase of 9% to $11.3M (expense), Miscellaneous income (expense) decrease of 99% to $8K (income).
Equity composition
Common Stock $.001 Par, 04/11, 100M auth., 29,021,460 issd., Insiders control approx. 0.08%. IPO: 4/06 5,000,000 shs. @ $9per share by Deutsche Bank Securities. 8/15, 1-for-7 reverse stock split.
Industry: | Biotechnology & Medical Research (NEC) |
12770 High Bluff Drive, Suite 150
SAN DIEGO
CALIFORNIA 92130
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com